ULBP2 Lentivirus (Macaca fascicularis/Cynomolgus)

Catalog #
78777
$850 *
Size: 500 µl x 2
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The ULBP2 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These viruses transduce cells with Macaca fascicularis (also known as crab-eating macaque or cynomolgus monkey) ULBP2 (XP_005552169.1) driven by an EF1A promoter. The lentiviruses also transduce a puromycin selection gene (Figure 1).

Figure 1: Schematic of the lenti-vector used to generate the cynomolgus ULBP2 Lentivirus.

Product Info
Storage and Usage
Citations
Supplied As
Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Formulation

The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee. 

Background

ULBP2 (UL16 binding protein) is a glycoprotein related to MHC class I molecules, that belongs to the family of unique length 16 (UL16) binding proteins. It is a stress-induced ligand for the activating NKG2D receptor in NK cells. It contains the MHC class-I-like α1-α2 domains but lacks the α3 region present in MICA/B proteins and uses GPI (glycosylphosphatidylinositol) as anchor to the plasma membrane. Stress-ligands respond to viral-infections, heat-shock or other cellular stress triggers, and are also crucial in immune surveillance. ULBP2 is expressed at low levels in normal tissues but overexpressed in several types of cancer (such as liver, breast, cervical and skin), with its levels linking to the severity of the prognosis. Targeting ULBP2, for example with miR-6071, was shown to reduce tumorigenicity in glioblastoma (GM). The use of ligands, small molecules, or other, to target the levels or action of ULBP2 can prove beneficial for NK-based cancer therapy.